The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
KropffM.BispingG.SchuckE.Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol.2007; 138(3): 330–337.
2.
DaviesF.E.WuP.JennerM.The combination of cyclophosphamide, velcade and dexamethasone (CVD) induces high response rates with comparable toxicity to velcade alone (V) and velcade plus dexamethasone (VD). Haematol.2007; 92(8): 1149–1150.
3.
FuW.DelasalleK.WangJ.Bortezomib-cyclophosphamide-dexamethasone for relapsing multiple myeloma [published online ahead of print June 18, 2011]. Am J Clin Oncol.
4.
KropffM.LiebischP.KnopS.DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma. Ann Hematol.2009; 88(11): 1125–1130.
5.
KnopS.LiebischP.WandtH.Bortezomib, IV cyclophosphamide, and dexamethasone (VelCD) as induction therapy in newly diagnosed multiple myeloma: Results of an interim analysis of the German DSMM XIa trial. Paper presented at: American Society of Clinical Oncology Annual Meeting; May 31, 2009; Orlando, FL.
6.
ReederC.B.ReeceD.E.KukretiV.Cyclophosphamide, bortezomib and dexamethasone (CyBorD) induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia.2009; 23(7): 1337–1341.
7.
BensingerW.I.JagannathS.VescioR.Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma. Br J Haematol.2009; 148(4): 562–568.
8.
ReederC.B.ReeceD.E.KukretiV.Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood.2010; 115(16): 3416–3417.
9.
NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma. V.1.2011. National Comprehensive Cancer Network Web site, www.nccn.org. Accessed July 14, 2011.
10.
NCCN Clinical Practice Guidelines in Oncology: Anti-emesis. V.3.2011. National Comprehensive Cancer Network Web site, www.nccn.org. Accessed July 19, 2011.
11.
Multinational Association of Supportive Care in Cancer antiemetic guidelines. Multinational Association of Supportive Care in Cancer Web site. Published March 2011. www.mascc.org. Accessed July 19, 2011.
12.
StillwellT.J.BensonR.C.Cyclophosphamide-induced hemorrhagic cystitis. A review of 100 patients. Cancer.1988; 61(3): 451–457.
NCCN Clinical Practice Guidelines in Oncology: Myeloid Growth Factors. V.1.2011. National Comprehensive Cancer Network Web site, www.nccn.org. Accessed August 3, 2011.
16.
SmithT.J.KhatcheressianJ.LymanG.H.2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol.2006; 24: 3187–3205.
17.
AronoffG.R.BennettW.M.BernsJ.S.Drug Prescribing in Renal Failure.5th ed.Philadelphia: American College of Physicians; 2007.
18.
KintzelP.E.DorrR.T.Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21(1): 33–64.
19.
KingP.D.PerryM.C.Hepatotoxicity of chemothearpy. The Oncologist.2001; 6(2): 162–176.
20.
FloydJ.MirzaI.SachsB.PerryM.C.Hepatotoxicity of chemotherapy. Semin Oncol.2006; 33(1): 50–67.
